The ECTRIMS Podcast
von The European Committee for Treatment and Research in Multiple Sclerosis
- wöchentlichErscheinungsrhythmus
- 23 mintypische Länge
- vor 2 Tagenletzte Folge
Folgenzu den neuesten
What's Next for MS Treatment? Key Takeaways from ECTRIMS 2025
What were the biggest developments in multiple sclerosis treatment at ECTRIMS 2025? As the 41st Congress came to a close in Barcelona, attention turned to new clinical trial results and what they could mean for the future of MS care. Dr. Sh
New MS Research and Treatment Advances: Highlights from ECTRIMS 2025 | Day Two
What were some of the most important new developments in multiple sclerosis research and treatment at ECTRIMS 2025? Dr. Barry Singer, Director and Founder of The MS Center for Innovations in Care, joins host Brett Drummond to unpack the key
Day 1 Highlights of ECTRIMS 2025
The 41st Congress of ECTRIMS opened in Barcelona with Professor Maria Pia Amato of the University of Florence delivering the ECTRIMS Lecture. In this conversation with host Brett Drummond, she highlights the key takeaways from Day One of EC
Pre-Day Highlights of ECTRIMS 2025
Direct from Barcelona, listen to Alvaro Cobo Calvo from the Multiple Sclerosis Center of Catalonia (Cemcat) and host Brett Drummond discuss the highlights of ECTRIMS 2025 Pre-Day, which is focused on specialised topics in MS and related neu
2024 Revisions of the McDonald Diagnostic Criteria: What Neurologists Need to Know
The 2024 Revisions of the McDonald Diagnostic Criteria for MS have been published in The Lancet Neurology. What do these changes mean for clinical practice? In this episode, we are joined by two authors of the paper: Prof. Xavier Montalban,
Genetics and MS: Recent Discoveries and Future Directions
Genetics not only influence the risk of developing multiple sclerosis (MS), but also affect how the disease progresses and how patients respond to different treatments. Professor Philip De Jager, Chief of Neuroimmunology at Columbia Univers
The Expanding Role of Patient-Reported Outcomes in MS Research
Patient-reported outcomes (PROs) have become a critical tool for capturing the lived experience of multiple sclerosis (MS), offering a perspective that extends beyond traditional clinical and imaging metrics. As research increasingly priori
Biomarkers in MS
Biomarkers are one of the most exciting and fast-evolving areas in multiple sclerosis research, offering promise for earlier diagnosis, accurate prognosis, and truly personalised treatment. Yet despite their potential, there is still signif
BTK Inhibitors: The Tolebrutinib Trial Results
Over the past few years, the MS research community has been following developments in a new class of therapies called Bruton's tyrosine kinase inhibitors (BTKis). At ECTRIMS 2024, the results of two tolebrutinib trials were presented as lat
The Role of Diet in Managing MS
What do the latest research findings tell us about the role diet can play in the management of multiple sclerosis (MS)? How should neurologists talk about diet with their patients? While people living with MS may view their food choices as
Autologous Haematopoietic Stem Cell Transplantation for MS
Autologous haematopoietic stem cell transplantation (AHSCT) has gained considerable attention in recent years as a treatment option for multiple sclerosis (MS). As long-term clinical trial data on AHSCT continues to grow, there is increasin
How Real-World Data Is Shaping MS Treatment
The rise of multiple sclerosis (MS) registries worldwide has transformed MS research, providing access to vast clinical data spanning years. This development also triggers critical conversations about how best to use real-world data to answ
Fatigue in Multiple Sclerosis
Fatigue is a common symptom of multiple sclerosis, significantly impacting the quality of life of people living with the disease. In this episode, Dr. Anne-Laure Dubessy of Hôpital Pitié-Salpêtrière in Paris and Professor Iris-Katharina Pen
Advancing MS Knowledge through the ECTRIMS Fellowship
The recent ECTRIMS 2024 in Copenhagen showcased the work of young scientific investigators, including this year's ECTRIMS Fellowship recipients Oscar Ayala from Colombia and Zuhal Abasiyanik from Turkey. Every year, ECTRIMS awards fellowshi
Addressing Diversity in MS Research and Care
Nearly three million people worldwide are living with multiple sclerosis (MS), affecting individuals from diverse geographical, ethnic, racial, and socio-economic backgrounds. This diversity raises important questions about how these factor
Paediatric Multiple Sclerosis
While paediatric onset multiple sclerosis is relatively rare, it presents unique challenges. Extensive research efforts are taking place around the world to better understand the disease mechanism of paediatric MS and the similarities and d
MS Prodrome: Implications and Future Research Directions
If you talk to someone living with MS about their journey, one of the first things they will tell you is that they knew something was wrong long before they received their diagnosis. While this anecdotal evidence has been commonly discussed
Future MS Therapeutics
Significant progress has been made in multiple sclerosis (MS) treatments over the past 20 years. What does the next 20 years hold for MS therapies? What novel targets are being investigated? What clinical trials are in the pipeline and when
MS Nurses at ECTRIMS 2024
Nurses play a specialised and unique role in the journey of people living with multiple sclerosis (MS). At ECTRIMS 2024, MS nurses showcased their experiences and insights into how to effectively support patients. In this episode, host Bret
Patient Community Day Highlights of ECTRIMS 2024: Part II
The Patient Community Day of ECTRIMS 2024 brought together people living with multiple sclerosis (MS), medical professionals, researchers, and advocates in two interactive sessions. They explored the forefront of MS research and treatment,
Patient Community Day Highlights of ECTRIMS 2024: Part I
The Patient Community Day of ECTRIMS 2024 brought together people living with multiple sclerosis (MS), medical professionals, researchers, and advocates in two interactive sessions. They explored the forefront of MS research and treatment,
Day 3 Highlights of ECTRIMS 2024
Former ECTRIMS President and MS Journal Editor-in-Chief Alan Thompson and host Brett Drummond wrap up the last day of ECTRIMS 2024 with their final thoughts and insights.
Day 2 Highlights of ECTRIMS 2024
Anne Helme, Head of Research at MSIF, and host Brett Drummond discuss the key takeaways unveiled on the second day of ECTRIMS 2024 in Copenhagen, as well as the value of global collaboration.
Day 1 Highlights of ECTRIMS 2024
ECTRIMS Vice President Bruno Stankoff highlights the most relevant insights from day one of ECTRIMS 2024 in Copenhagen, and provides a glimpse of what to expect from the ECTRIMS society in the coming year.
Pre-Day Highlights of ECTRIMS 2024
Listen to Romain Marignier from CHU de Lyon and host Brett Drummond discuss highlights of ECTRIMS' new Pre-Day on NMOSD, MOGAD, and other rare neurological conditions.
Episode 35: NMOSD and MOGAD Part II
Misdiagnosing multiple sclerosis (MS) is not uncommon. Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disorder (MOGAD) can have clinical manifestations similar to MS. In this two-part episode
Episode 35: NMOSD and MOGAD Part I
Misdiagnosing multiple sclerosis (MS) is not uncommon. Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disorder (MOGAD) can have clinical manifestations similar to MS. In this two-part episode
ECTRIMS-EAN Vaccination Consensus Statement (eanCast)
The following episode has been produced by the European Academy of Neurology (EAN) in collaboration with the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and has been published on both the EAN and ECTRIMS P
Environmental, Genetic, and Epigenetic Risk Factors in MS
Multiple sclerosis (MS) is a complex and multifaceted neurological disorder. While MS has a genetic component, it is not a classic genetic disease. For this reason, a large amount of research has been done to identify environmental factors
Myelin plasticity and repair
The next major step forward in the management of MS involves finding treatments that can repair damaged myelin. If successful, it would offer the potential to start to reverse some of the symptoms experienced by people living with MS. Bruno
